MINA53-IN-1 is a selective MINA53 inhibitor with an IC50 of 1.5 μM. MINA53-IN-1 induces DNA damage, cell cycle arrest and apoptosis in tumor cells. MINA53-IN-1 can be used for cancer research [1].
In Vitro, MINA53-IN-1 (compound 10) inhibits the proliferation of HL-60 acute promyelocytic leukemia cells after 48 h, with an IC50 of 14 μM[1]. MINA53-IN-1 (10-100 μM; 72-120 h) reduces the viability of U-87MG glioblastoma cells, MNK-45 gastric cancer cells and HeLa cervical cancer cells in a dose- and time-dependent manner[1]. MINA53-IN-1 (10-20 μM; 24 h) induces DNA damage, G2/M cell cycle arrest and apoptosis in U-87MG cells, and acts synergistically with Doxorubicin to enhance apoptosis[1].
References:
[1]. Nowak RP, et al. First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. J Med Chem. 2021;64(23):17031-17050.
In Vitro, MINA53-IN-1 (compound 10) inhibits the proliferation of HL-60 acute promyelocytic leukemia cells after 48 h, with an IC50 of 14 μM[1]. MINA53-IN-1 (10-100 μM; 72-120 h) reduces the viability of U-87MG glioblastoma cells, MNK-45 gastric cancer cells and HeLa cervical cancer cells in a dose- and time-dependent manner[1]. MINA53-IN-1 (10-20 μM; 24 h) induces DNA damage, G2/M cell cycle arrest and apoptosis in U-87MG cells, and acts synergistically with Doxorubicin to enhance apoptosis[1].
References:
[1]. Nowak RP, et al. First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. J Med Chem. 2021;64(23):17031-17050.